Driven by a strong performance in the oncology franchise (Somatuline, Cabometyx and Onivyde) and robust operational leverage, revenue and profitability targets exceeded management’s expectations in FY18. As the positive growth momentum is likely to continue in FY19 as well, we anticipate that the financial targets set for FY20 would be achieved a year in advance. An acquisition is also on the cards, which also explains a flat dividend for FY18, despite a c.35% increase in EPS.
15 Feb 2019
FY18 finishes on a high; robust outlook for the next year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY18 finishes on a high; robust outlook for the next year
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
15 Feb 2019 -
Author:
Sumit Sayal -
Pages:
4
Driven by a strong performance in the oncology franchise (Somatuline, Cabometyx and Onivyde) and robust operational leverage, revenue and profitability targets exceeded management’s expectations in FY18. As the positive growth momentum is likely to continue in FY19 as well, we anticipate that the financial targets set for FY20 would be achieved a year in advance. An acquisition is also on the cards, which also explains a flat dividend for FY18, despite a c.35% increase in EPS.